Role of vaccination in the sustainability of healthcare systems.

Nathalie Largeron, Pierre Lévy, Jürgen Wasem, Xavier Bresse
Author Information
  1. Nathalie Largeron: Sanofi Pasteur MSD, Lyon, France.
  2. Pierre Lévy: LEDa-LEGOS, Université Paris-Dauphine, Paris, France.
  3. Jürgen Wasem: Institute of Health Care Management and Research, Universität Duisburg, Essen, Germany.
  4. Xavier Bresse: Sanofi Pasteur MSD, Lyon, France.

Abstract

The use of vaccines to prevent diseases in children, adults, and the elderly results in fewer medical visits, diagnostic tests, treatments, and hospitalisations, which leads to substantial savings in healthcare costs each year in Europe and elsewhere. Vaccines also contribute to reducing resource utilisation by preventing nosocomial infections, such as rotavirus gastroenteritis, which can increase hospital stays by 4-12 days. Vaccination also has an important role in the prevention of cancers with, for example, human papillomavirus or hepatitis B vaccines. Since the financial impact of cancer is high for patients, healthcare systems, and society as a whole, any cases prevented will reduce this impact. Newer vaccines, such as the herpes zoster vaccine, can provide an answer to unmet medical needs by preventing and reducing the severity of shingles and associated post-herpetic neuralgia, which are difficult conditions to treat. Thus, in the context of increasing pressure on healthcare budgets, vaccination can contribute to the sustainability of healthcare systems through reduced and more efficient use of healthcare resources.

Keywords

References

  1. Lancet. 2000 Jan 8;355(9198):93-7 [PMID: 10675165]
  2. BMJ. 2002 Apr 6;324(7341):809 [PMID: 11934772]
  3. Pharmacoeconomics. 2004;22(13):839-55 [PMID: 15329030]
  4. Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S12-21 [PMID: 16397425]
  5. Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S7-S11 [PMID: 16397431]
  6. Age Ageing. 2006 Mar;35(2):132-7 [PMID: 16431855]
  7. Vaccine. 2006 May 8;24(19):4212-21 [PMID: 16546308]
  8. Curr Med Res Opin. 2006 Apr;22(4):663-70 [PMID: 16684427]
  9. Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18 [PMID: 16965399]
  10. Gynecol Obstet Fertil. 2007 Feb;35(2):107-13 [PMID: 17270482]
  11. Vaccine. 2007 May 16;25(20):3962-70 [PMID: 17395343]
  12. J Infect Dis. 2007 May 1;195 Suppl 1:S36-S44 [PMID: 17539193]
  13. Vaccine. 2007 Aug 21;25(34):6348-58 [PMID: 17629598]
  14. BJOG. 2008 Jul;115(8):947-56 [PMID: 18503574]
  15. BMC Infect Dis. 2010 Aug 09;10:235 [PMID: 20696065]
  16. Rev Epidemiol Sante Publique. 2010 Dec;58(6):393-401 [PMID: 21094001]
  17. Vaccine. 2011 Jul 18;29(32):5245-9 [PMID: 21616117]
  18. Pharmacoeconomics. 2012 Jan;30(1):1-16 [PMID: 22201520]
  19. Cancer Prev Res (Phila). 2012 Jan;5(1):24-9 [PMID: 22219163]
  20. Vaccine. 2012 Mar 2;30(11):1993-8 [PMID: 22226861]
  21. BMC Cancer. 2012 Jan 20;12:30 [PMID: 22260541]
  22. Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):71-94 [PMID: 22280198]
  23. BMC Infect Dis. 2012 Mar 19;12:62 [PMID: 22429601]
  24. Int J Cancer. 2013 Mar 1;132(5):1133-45 [PMID: 22752881]
  25. Vaccine. 2012 Dec 14;30(52):7443-6 [PMID: 23084849]
  26. Clin Microbiol Infect. 2012 Dec;18 Suppl 6:5-12 [PMID: 23121549]
  27. BMC Public Health. 2012 Nov 12;12:968 [PMID: 23146107]
  28. Therapie. 2012 Sep-Oct;67(5):471-6 [PMID: 23241257]
  29. Vaccine. 2013 Feb 4;31(7):1117-22 [PMID: 23262168]
  30. Acta Paediatr. 2013 Apr;102(4):e158-63 [PMID: 23289533]
  31. J Med Econ. 2013;16(6):763-76 [PMID: 23565814]
  32. BMJ. 2013 Apr 18;346:f2032 [PMID: 23599298]
  33. Expert Rev Vaccines. 2013 Sep;12(9):1085-94 [PMID: 24024871]
  34. Int J Cancer. 2014 May 1;134(9):2264-8 [PMID: 24174175]
  35. Vaccine. 2013 Nov 22;31 Suppl 8:I1-31 [PMID: 24229716]
  36. MMWR Morb Mortal Wkly Rep. 2014 Apr 25;63(16):352-5 [PMID: 24759657]
  37. BMC Public Health. 2014 Aug 07;14:813 [PMID: 25103091]
  38. Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):913-27 [PMID: 25189087]
  39. Expert Rev Vaccines. 2014 Nov;13(11):1279-90 [PMID: 25256262]
  40. BMJ. 2015 Jan 06;350:g7584 [PMID: 25567037]
  41. BMC Public Health. 2015 Feb 27;15:193 [PMID: 25880058]
  42. J Prim Prev. 2015 Aug;36(4):259-73 [PMID: 26032932]
  43. J Mark Access Health Policy. 2015 Aug 12;3:null [PMID: 27123171]
  44. J Mark Access Health Policy. 2015 Aug 12;3:null [PMID: 27123182]
  45. J Mark Access Health Policy. 2015 Aug 12;3:null [PMID: 27123189]

Word Cloud

Created with Highcharts 10.0.0healthcareusevaccinescansystemsvaccinationmedicalcostsalsocontributereducingresourcepreventingnosocomialinfectionscancersimpactsustainabilitypreventdiseaseschildrenadultselderlyresultsfewervisitsdiagnosticteststreatmentshospitalisationsleadssubstantialsavingsyearEuropeelsewhereVaccinesutilisationrotavirusgastroenteritisincreasehospitalstays4-12daysVaccinationimportantrolepreventionexamplehumanpapillomavirushepatitisBSincefinancialcancerhighpatientssocietywholecasespreventedwillreduceNewerherpeszostervaccineprovideanswerunmetneedsseverityshinglesassociatedpost-herpeticneuralgiadifficultconditionstreatThuscontextincreasingpressurebudgetsreducedefficientresourcesRole

Similar Articles

Cited By